Hypertrophic obstructive cardiomyopathy: What, when, why, for whom?

Carlos A. Mestres, Thomas Bartel, Antonio Sorgente, Silvana Müller, Christiane Gruner, Joseph Dearani, Eduard Quintana

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Hypertrophic cardiomyopathy is the most common genetic cardiovascular disorder and is associated with symptoms of heart failure and increased risk of sudden cardiac death. The most common condition is obstruction of the left ventricular outflow tract. Surgical septal myectomy and alcohol septal ablation are the 2 accepted modes of septal reduction therapy and are indicated when there are advanced symptoms and a peak left ventricular outflow gradient ≥ 50 mmHg. Advantages of alcohol septal ablation are limited groin approach, reduction of obstruction of the left ventricular outflow tract and functional improvement, but there are higher chances for intracardiac device implantation and residual obstruction. Septal myectomy offers very low mortality, absolute and immediate resolution of obstruction of the left ventricular outflow tract and survival comparative to a matched general population with almost negligible residual obstruction. It is recommended that patients with obstructive hypertrophic cardiomyopathy should be treated at experienced centres.

Original languageEnglish (US)
Pages (from-to)700-707
Number of pages8
JournalEuropean Journal of Cardio-thoracic Surgery
Volume53
Issue number4
DOIs
StatePublished - Apr 1 2018

Keywords

  • Alcohol septal ablation
  • Obstructive hypertrophic cardiomyopathy
  • Septal myectomy
  • Septal reduction therapy

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Hypertrophic obstructive cardiomyopathy: What, when, why, for whom?'. Together they form a unique fingerprint.

  • Cite this

    Mestres, C. A., Bartel, T., Sorgente, A., Müller, S., Gruner, C., Dearani, J., & Quintana, E. (2018). Hypertrophic obstructive cardiomyopathy: What, when, why, for whom? European Journal of Cardio-thoracic Surgery, 53(4), 700-707. https://doi.org/10.1093/ejcts/ezy020